{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:00:57Z","timestamp":1789664457498,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jad.2024.01.268","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T17:23:41Z","timestamp":1707153821000},"page":"904-914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials"],"prefix":"10.1016","volume":"351","author":[{"given":"Anita H.","family":"Clayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellison","family":"Suthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Deligiannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Meltzer-Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Gervitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayveer","family":"Bonthapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.01.268_bb0005","series-title":"ACOG Committee Opinion No. 757: Screening for Perinatal Depression","author":"ACOG","year":"2018"},{"key":"10.1016\/j.jad.2024.01.268_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265928","article-title":"Antidepressants and health-related quality of life (HRQoL) for patients with depression: analysis of the medical expenditure panel survey from the United States","volume":"17","author":"Almohammed","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2024.01.268_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(a) receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.01.268_bb0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jad.2024.01.268_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/002076402128783235","article-title":"Depression and quality of life: results of a follow-up study","volume":"48","author":"Angermeyer","year":"2002","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0030","doi-asserted-by":"crossref","first-page":"21r14328","DOI":"10.4088\/JCP.21r14328","article-title":"Impact of major depressive disorder on comorbidities: a systematic literature review","volume":"83","author":"Arnaud","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0035","doi-asserted-by":"crossref","first-page":"22r03330","DOI":"10.4088\/PCC.22r03330","article-title":"Impact of treating depression on associated comorbidities: a systematic literature review","volume":"25","author":"Arnaud","year":"2023","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.15585\/mmwr.mm6919a2","article-title":"Vital signs: postpartum depressive symptoms and provider discussions about perinatal depression - United States, 2018","volume":"69","author":"Bauman","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jad.2024.01.268_bb0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1185\/030079907X178757","article-title":"Interpreting score differences in the SF-36 vitality scale: using clinical conditions and functional outcomes to define the minimally important difference","volume":"23","author":"Bjorner","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2024.01.268_bb0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jad.2014.09.005","article-title":"Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder","volume":"170","author":"Blum","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0055","series-title":"Mental Disorders around the World","first-page":"41","article-title":"Major depressive disorders","author":"Bromet","year":"2018"},{"key":"10.1016\/j.jad.2024.01.268_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1744-859X-9-33","article-title":"The factors influencing depression endpoints research (FINDER) study: final results of Italian patients with depression","volume":"9","author":"Caruso","year":"2010","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0065","series-title":"Substance Abuse and Mental Health Services (Administration)","article-title":"Results from the 2021 National Survey on drug use and health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2022"},{"key":"10.1016\/j.jad.2024.01.268_bb0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jad.2022.11.033","article-title":"The motivation and energy inventory (MEI): analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study","volume":"323","author":"Christensen","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4088\/JCP.10m06314","article-title":"Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study","volume":"73","author":"Ciudad","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0080","doi-asserted-by":"crossref","first-page":"22m14445","DOI":"10.4088\/JCP.22m14445","article-title":"Zuranolone in major depressive disorder: results from MOUNTAIN-a phase 3, multicenter, double-blind, randomized, placebo-controlled trial","volume":"84","author":"Clayton","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0085","doi-asserted-by":"crossref","unstructured":"Clayton, A.H., Lasser, R., Parikh, S.V., Iosifescu, D.V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S.J., Doherty, J., 2023b. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 trial. Am J psychiatry, appiajp20220459.","DOI":"10.1176\/appi.ajp.20220459"},{"key":"10.1016\/j.jad.2024.01.268_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000214442","article-title":"Quality of life measurement in antidepressant trials. Is there an added value?","volume":"78","author":"De Fruyt","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2024.01.268_bb0095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0100","doi-asserted-by":"crossref","first-page":"22m14475","DOI":"10.4088\/JCP.22m14475","article-title":"Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression","volume":"84","author":"Deligiannidis","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0105","first-page":"14","article-title":"Quality of life assessment in antidepressant treatment of patients with depression and\/or anxiety disorder","volume":"31","author":"Dzevlan","year":"2019","journal-title":"Mater. Soc."},{"key":"10.1016\/j.jad.2024.01.268_bb0110","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc09-0785","article-title":"Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Echeverry","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2024.01.268_bb0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/HTR.0000000000000322","article-title":"Sertraline for major depression during the year following traumatic brain injury: a randomized controlled trial","volume":"32","author":"Fann","year":"2017","journal-title":"J. Head Trauma Rehabil."},{"key":"10.1016\/j.jad.2024.01.268_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.infbeh.2009.10.005","article-title":"Postpartum depression effects on early interactions, parenting, and safety practices: a review","volume":"33","author":"Field","year":"2010","journal-title":"Infant Behav. Dev."},{"key":"10.1016\/j.jad.2024.01.268_bb0125","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.01.268_bb0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0135","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ahj.2007.02.024","article-title":"A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure","volume":"153","author":"Gottlieb","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jad.2024.01.268_bb0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2024.01.268_bb0145","doi-asserted-by":"crossref","unstructured":"Habert, J., Katzman, M.A., Oluboka, O.J., McIntyre, R.S., McIntosh, D., MacQueen, G.M., Khullar, A., Milev, R.V., Kjernisted, K.D., Chokka, P.R., Kennedy, S.H., 2016. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim care companion CNS Disord 18, PCC.15r01926.","DOI":"10.4088\/PCC.15r01926"},{"key":"10.1016\/j.jad.2024.01.268_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/16506073.2017.1304445","article-title":"Effect of treatments for depression on quality of life: a meta-analysis","volume":"46","author":"Hofmann","year":"2017","journal-title":"Cogn. Behav. Ther."},{"key":"10.1016\/j.jad.2024.01.268_bb0155","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.01.268_bb0160","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.286.23.2947","article-title":"Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial","volume":"286","author":"Kroenke","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.01.268_bb0165","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/0269881117719261","article-title":"Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: a pooled analysis","volume":"31","author":"Lam","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.01.268_bb0170","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jad.2009.10.002","article-title":"Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders","volume":"123","author":"Lee","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0175","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.apnu.2003.10.004","article-title":"Role functioning and symptom remission in women with postpartum depression after antidepressant treatment","volume":"17","author":"Logsdon","year":"2003","journal-title":"Arch. Psychiatr. Nurs."},{"key":"10.1016\/j.jad.2024.01.268_bb0185","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3alpha-Hydroxy-3beta-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5beta-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (gamma-aminobutyric acid)(a) receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jad.2024.01.268_bb0190","series-title":"User\u2019s Manual for the SF-36v2 Health Survey","author":"Maruish","year":"2011"},{"key":"10.1016\/j.jad.2024.01.268_bb0195","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jad.2011.06.028","article-title":"Development and validation of a patient-report measure of fatigue associated with depression","volume":"134","author":"Matza","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2c","article-title":"Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication","volume":"31","author":"McClintock","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.01.268_bb0205","doi-asserted-by":"crossref","first-page":"MS253","DOI":"10.1097\/00005650-199205001-00025","article-title":"The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the medical outcomes study","volume":"30","author":"McHorney","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.jad.2024.01.268_bb0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med. Care"},{"key":"10.1016\/j.jad.2024.01.268_bb0215","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/03007995.2019.1652053","article-title":"Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2024.01.268_bb0220","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1542\/peds.2005-1551","article-title":"The timing of maternal depressive symptoms and mothers\u2019 parenting practices with young children: implications for pediatric practice","volume":"118","author":"McLearn","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jad.2024.01.268_bb0225","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.4088\/JCP.15m10573","article-title":"Early improvement of specific symptoms predicts subsequent recovery in bipolar depression: reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data","volume":"78","author":"Mizushima","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0230","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuropharm.2016.10.010","article-title":"Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism","volume":"113","author":"Modgil","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.01.268_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00737-008-0217-0","article-title":"Perceived and observed mother-child interaction at time of hospitalization and release in postpartum depression and psychosis","volume":"11","author":"Noorlander","year":"2008","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.jad.2024.01.268_bb0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.vhri.2021.12.001","article-title":"Health-related quality of life over 6 months in patients with major depressive disorder who started antidepressant monotherapy","volume":"30","author":"Noto","year":"2022","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jad.2024.01.268_bb0245","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1542\/peds.110.6.1169","article-title":"Primary care pediatricians' roles and perceived responsibilities in the identification and management of maternal depression","volume":"110","author":"Olson","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jad.2024.01.268_bb0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2296-8-34","article-title":"Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial","volume":"8","author":"Paile-Hyvarinen","year":"2007","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.jad.2024.01.268_bb0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jmwh.2008.02.016","article-title":"Functional status outcomes in mothers with and without postpartum depression","volume":"53","author":"Posmontier","year":"2008","journal-title":"J. Midwifery Womens Health"},{"key":"10.1016\/j.jad.2024.01.268_bb0260","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1192\/bjp.bp.106.028555","article-title":"Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis","volume":"190","author":"Posternak","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.genhosppsych.2015.12.003","article-title":"Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey","volume":"39","author":"Pratt","year":"2016","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0270","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2008.05.021","article-title":"Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER","volume":"113","author":"Reed","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0275","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-244X-13-51","article-title":"Residual symptoms and functioning in depression, does the type of residual symptom matter?","volume":"13","author":"Romera","year":"2013","journal-title":"A post-hoc analysis. BMC Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0280","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2022.03.068","article-title":"Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder","volume":"308","author":"Suthoff","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.268_bb0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1592\/phco.21.2.189.34102","article-title":"Improved health-related quality of life with SSRIs and other antidepressants","volume":"21","author":"Taylor","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jad.2024.01.268_bb0300","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0305","series-title":"Approval Package for Golimumab","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.jad.2024.01.268_bb0310","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41398-021-01663-6","article-title":"Mapping global prevalence of depression among postpartum women","volume":"11","author":"Wang","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0315","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.jad.2024.01.268_bb0320","doi-asserted-by":"crossref","first-page":"22com14600","DOI":"10.4088\/JCP.22com14600","article-title":"The relationship between major depressive disorder and multiple medical conditions: a call to improve integrated care services","volume":"83","author":"Weir","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0325","series-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"WHO","year":"1992"},{"key":"10.1016\/j.jad.2024.01.268_bb0330","series-title":"International Statistical Classification of Diseases and Related Health Problems, 11th Revision (ICD-11)","author":"WHO","year":"2018"},{"issue":"6","key":"10.1016\/j.jad.2024.01.268_bb0335","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/acps.13541","article-title":"Antidepressants and quality of life in patients with major depressive disorder - systematic review and meta-analysis of double-blind, placebo-controlled RCTs","volume":"147","author":"Wiesinger","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2024.01.268_bb0340","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12888-017-1471-3","article-title":"Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2024.01.268_bb0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ajp.163.1.148","article-title":"How should remission from depression be defined? The depressed patient\u2019s perspective","volume":"163","author":"Zimmerman","year":"2006","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T02:55:54Z","timestamp":1720061754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":67,"alternative-id":["S0165032724002933"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.268","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}